# LOcoregional vs Systemic Therapy in Patients With BCLC Stage B HCC

> **NCT05537402** · PHASE2 · TERMINATED · sponsor: **University of Texas Southwestern Medical Center** · enrollment: 1 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Atezolizumab and bevacizumab
- **RADIATION:** transarterial chemoembolization (TACE) or transarterial radioembolization (TARE

## Key facts

- **NCT ID:** NCT05537402
- **Lead sponsor:** University of Texas Southwestern Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-09-27
- **Primary completion:** 2025-06-06
- **Final completion:** 2025-06-06
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** The decision was made to close the study to enrollment due to poor overall accrual and the inability to meet the 31% overall enrollment goal.
- **Last updated:** 2025-09-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05537402

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05537402, "LOcoregional vs Systemic Therapy in Patients With BCLC Stage B HCC". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05537402. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*